Psychedelics in the headlines again as research fast-tracks and policy shifts ease access. Psilocybin: a prodrug from 200+ fungi, now under fast FDA reviews for hard-to-treat mental illness.
The US government has implemented new policies to accelerate research and development of psychedelics, including psilocybin, MDMA, and ibogaine. The move involves FDA fast-tracking and funding for state-level studies, aiming to improve treatments for mental health and addiction. This follows recent political and scientific developments.